To include your compound in the COVID-19 Resource Center, submit it here.

FDA grants Novartis' Kymriah Priority Review for DLBCL

Novartis AG (NYSE:NVS; SIX:NOVN) said FDA accepted and granted Priority Review to an sBLA for Kymriah tisagenlecleucel to

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE